BGDO AWARD 2023
The BGDO wishes to stimulate scientific research work and communication in the field of gastrointestinal oncology, performed mainly in Belgium. For this purpose, the BGDO will grant this year an award to one or two scientific projects dealing with epidemiology, basic or translational research, clinical research, or registry in digestive oncology.
Apply for the BGDO Awards. You can find the rules here.
The BGDO Award 2023 will be accorded to a researcher or a team of researchers (the applicant him/herself has to be younger than 40) in the field of GI oncology who propose an original research project that will be conducted in an outstanding manner in Belgium and may have a significant impact on our knowledge and/or management of gastrointestinal cancers.
At least one of the researchers per team should be a member of the BGDO.
The project should be realistically achievable and completed within two years.
The winner(s) will be granted EUR 2500 to cover the research work.
All projects will be evaluated by a jury who will select two projects according to the scope of the BGDO award. The jury will be composed of the BGDO board representatives and national oncology experts.
Each project should be sent before 23 December 2022, 2 pm to firstname.lastname@example.org.
BGDO DNET Award
The BGDO wishes to stimulate a project working on the Digestive Neuroendocrine Tumor registry.
The DNET is a registry to collect epidemiological and medicinal data of patients suffering from digestive neuro-endocrine tumours via an electronic database. The registry started in 2000. A lot of interesting are already available.
Again, the Award will be accorded to a researcher or a team of researchers (the applicant him/herself has to be younger than 40) who propose an original project that will be conducted in an outstanding and timely manner. At least one of the researchers per team should be a member of the BGDO.
As data are already available in the DNET registry, the project should be realistically achievable and completed within one year".
One research grant will be allocated depending on the quality of the projects submitted.
The winner will be granted EUR 2500 to cover the research work.
BGDO AWARD Winners
Congratulations to them.
|2021||Sarah Cappuyns||The ongoing search for biomarkers in systemic treatment of advanced Hepatocellular carcinoma|
|2019||Jeroen Dekervel||Methylome analysis of circulating free DNA in bile fluid to diagnose cholangiocarcinoma|
|2017||Julie Jacobs||Paving the way for CD70 as novel target for immunotherapy in colorectal cancer|
|2015||Elsa Ghurburrun||Pathogenesis of ductal pancreatic tumours|
|2015||Andrei Turtoi||Discovery of Novel and Optimization of Existing Treatments
for Hepatocellular Carcinoma
|2013||Bénédicte Delire||The tumor microenvironment and hepatocellular carcinoma (HCC): what is the interest of targeting liver fibrosis in the treatment of HCC?|
|2013||Francesco Puléo||Impact of Notch pathway in predicting outcome and resistance to adjuvant therapy in resected pancreatic cancer|
|2011||Hannah van Malenstein||Development of a Prognostic Gene Set Based on Chronic Hypoxia in Patients with Colon Carcinoma and its Performance in Paraffin Embedded Tissue|
|2011||Jaarke Vannoote||High definition endoscopy and virtual chromoendoscopy versus standard resolution endoscopy in the detection of colon polyps|
|2009||Annelies Debucquoy||Biomarkers predicting resistance against anti-VEGF therapies in rectal cancer.|
|2009||Christel Vangestel||Early apoptotic tumour response and tumour glucose utilization by SPECT/PET imaging in a colorectal tumour model.|
|2006||Raphael Maréchal||Evaluation of prognostic and predictive value of circulating tumor cells (CTC) in colorectal cancer (CRC).|
|2006||Sabine Tejpar||Response Prediction to EGFR targeted therapies in colorectal cancer|
BGDO DNET AWARD Winners
Congratulations to them.
|2021||Timon Vandamme||Sequential everolimus and sunitinib treatment after failure of somatostatin analogues in DNET, a Belgian prospective registry of neuroendocrine neoplasms|
BGDO Prize Best presentation Belgian Week
|2022||Astrid Van Den Eynde||Development of a novel off-the-shelf cell-based immunotherapy to eradicate CD70-positive cancer associated fibroblasts in metastatic colorectal cancer.|
|2020||Sofie De Meulder||Real world incidence of microsatellite instability or EBV positivity in a Belgian cohort of patients with adenocarcinoma of the esophagus, gastroesophageal junction and stomach|
|2019||Anne Demols||Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced (non resectable) and metastatic biliary tumors: a randomized double-blinded placebo-controlled phase II trial.|
|2017||G. Vervloet||ypT0N+: the outcasts in pathological complete tumor response after neoadjuvant chemoradiation for esophageal cancer. How do they fare?|
|2016||Marc Van Den Eynde||Metastatic colorectal cancer has heterogeneous immune microenvironment and mutational expression|
|2015||Sofie Van Binnebeek|